Amarin jumps on FDA priority review for heart drug

Irish company’s Vascepa on track for earlier than expected approval

Irish VC group Fountain Healthcare Partners raises €118m

Group beats €100m target and intends to invest the bulk of the fund in Europe and US

Amarin’s heartwarming bulletin for firm’s shareholders

Stock advances over fivefold in 12 months on evidence of medicine’s cardiovascular effect

Amarin to seek European approval for heart drug Vascepa

Clinical trials show Irish company’s fish-oil drug cut incidence of heart attacks and strokes

Dalata named company of the year at ‘Irish Times’ business awards

The Republic’s largest hotel group has more than 9,000 rooms across its portfolio

The Irish Times Company of the Year: the four finalists

Stripe, Dalata, Glanbia and Amarin shortlisted on back of standout years

Business 2018: the winners and the losers

The last 12 months proved to be another year of mixed fortunes in corporate Ireland

Irish firm Amarin confirms heart drug success

Some concern over neutrality of placebo and whether it might have boosted Vascepa data

Tetrarch buys 470 acres of Howth, bankers’ bonuses and Ryanair’s turbulent week

‘Business Today: the best news, analysis and comment from ‘The Irish Times’ business desk

Amarin – an overnight success 10 years in the making

After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market

Amarin surges as trial results exceed expectations

Company’s Vascepa drug proves effective in reducing risk from stroke and heart attack

Taoiseach defends relationship with chair of firm that HSE chief has joined

Varadkar backs Minister’s consent granted to O’Brien to take up board role at US firm

Amarin reports 59% jump in sales for Vascepa drug

Irish biotech’s drug used to treat US patients with high levels of blood fats

52 Places to Go in 2017

There are thousands of getaways waiting to be explored. Here are some ideas to get you started

Amarin reports strong sales growth for Vascepa

Company targets expanded market share for fish oil drug that cuts risk of heart disease

Amarin reports 62% rise in fourth quarter sales of Vascepa

Costs, including ongoing R&D, means the company reports loss of $21.9 million for the quarter and $115.2 million for full year

Drug minnow Amarin downs FDA in constitutional battle

Irish pharma firm wins major victory over FDA on off-label promotion of its drug Vascepa

Irish drug company Amarin defeats FDA in US lawsuit

US court rules regulator cannot bar company promoting off label use for drug

Cantillon: Amarin faces down the mighty FDA

Small Irish pharma group sues US regulator over restricting its right to free speech

Pharma group Amarin sues FDA over right to brief doctors on drug

Dublin group says regulator refusal to allow it discuss off label use breaches US first amendment rights and puts it at a disadvantage to rival unregulated products

Amarin secures $52.8m to promote cardiovascular drug

Irish pharmaceuticals group says it raised the capital through new and existing investors

For your diary

Amarin slumps more than 20 per cent as drug appeal rejected

Regulator shuts door on plans to extend market for Vascepa

Amarin takes legal action against FDA over patent protection for Vascepa

Company continues to fight regulator as it reports $166m loss in first year of commercial operation for fish oil drug

Amarin slides on latest FDA setback

US health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug

Ask Joan

Pula and the islands, Harry Potter in a day, and Fiji

Amarin raises doubts over future prospects

Drug firms questions whether it can afford to fund trial central to growth plans

For your diary

Cantillon: Amarin in need of serious medicine

Company to slash staff numbers in an effort to curb operating costs.

Amarin shares slump on FDA panel rejection

Company fails to persuade advisory panel to back exponential expansion of market for cardiovascular drug

Amarin fails to secure backing of FDA panel for expanded use

FDA is scheduled to decide whether to clear the drug for wider use by December 20th

Cantillon: Amarin tests FDA appetite for fish oil drug

Stock value suggests even its proponents are not entirely sure of their ground

Amarin shares hit by ruling on generic drugs

Victory by Teva and Par in US case raises concern over prospects for cholesterol drug

Losses at Amarin widen despite strong revenues from new drug

Irish biopharma group regonised revenues of $5.5m from its new Vascepa drug in Q2

Cantillon: Little to keep pharma analysts busy in wake of Elan deal

Amarin announces plan to sell another 21.7 million shares

Proceeds will fund ongoing rollout of Vascepa fish oil drug in the US

Cantillon: Making sense of confusion in mid-range pharma M&A

Cluster of recent deals could each have an impact on Irish drug sector

YOU MAY ALSO LIKE...
The Irish Times ePaper

Food Month

Celebrate the best of food with The Irish Times

Stardust

Inquests into the nightclub fire that led to the deaths of 48 people